摘要
目的对原发性肝癌患者采用奥沙利铂联合表柔比星治疗的效果进行探究。方法选择枝江市人民医院收治的原发性肝癌患者126例纳入到本次研究当中,选取时间2017年1月—2019年5月。通过随机数字表法对这些患者实施分组处理,其中甲组有63例,乙组有63例。通过奥沙利铂对甲组患者予以治疗,在此基础之上,通过表柔比星对乙组患者予以治疗。比较两组的治疗效果及安全性。结果总有效率这一指标上,与甲组的数据相比,乙组明显更高,差异有统计学意义(P<0.05);两组治疗前的癌胚抗原水平、血清甲胎蛋白水平比较差异无统计学意义(P>0.05),治疗后,在癌胚抗原水平、血清甲胎蛋白水平这些数据方面,与甲组相比,乙组明显更低,差异有统计学意义(P<0.05);甲组的1年生存率为55.6%,甲组的1年生存率为74.6%,乙组的1年生存率明显高于甲组,差异有统计学意义(P<0.05);在不良反应发生率这一指标上,与甲组的数据相比,乙组明显更低,差异有统计学意义(P<0.05)。结论在原发性肝癌的临床治疗中,在应用奥沙利铂这一药物的基础上,再让患者使用表柔比星能达到比较理想的效果,能减少其肿瘤标志物,延长其生存时间,而且不良反应较少,具有较高的安全性。
Objective To investigate the efficacy of oxaliplatin combined with epirubicin in the treatment of patients with primary liver cancer.Methods A total of 126 patients with primary liver cancer admitted to Zhijiang People’s Hospital were included in this study.The selected period was from January 2017 to May 2019.The patients were grouped using a random number table,with 63 in group A and 63 in group B.Group A was treated with oxaliplatin,and group B was treated with epirubicin on top of that.The therapeutic effect and safety of the two groups were compared.Results The total effective rate of group B was significantly higher than that of group A,the difference was statistically significant(P<0.05).There were no significant differences in the levels of carcinoembryonic antigen and serum alpha-fetoprotein between the two groups before treatment(P>0.05).After treatment,the levels of carcinoembryonic antigen and serum alpha-fetoprotein in group B were significantly lower than those in group A,the differences were statistically significant(P<0.05).The 1-year survival rate of group A was 55.6%,and that of group A was 74.6%.The 1-year survival rate of group B was significantly higher than that of group A,the difference was statistically significant(P<0.05).In the index of the incidence of adverse reactions,the data of group B was significantly lower than that of group A,the difference was statistically significant(P<0.05).Conclusion In the clinical treatment of primary liver cancer,the use of epirubicin in patients on the basis of oxaliplatin can achieve a relatively ideal effect,can reduce the tumor markers,prolong the survival time,and has relatively high safety in terms of less adverse reactions.
作者
潘嫚
杨业勤
PAN Man;YANG Yeqin(Department of Oncology,Zhijiang People’s Hospital,Zhijiang Hubei 443200,China)
出处
《中国卫生标准管理》
2022年第23期119-122,共4页
China Health Standard Management
关键词
奥沙利铂
表柔比星
原发性肝癌
疗效
生存时间
不良反应
oxaliplatin
epirubicin
primary liver cancer
curative effect
survival time
adverse reactions
